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Abstract 12 
A Grignard-based batch process, for the preparation of Melitracen HCl, has been redesigned to 13 
fit a continuous reactor system. The Grignard addition is carried out at room temperature, with 14 
subsequent hydrolysis of the magnesium alkoxide intermediate followed by dehydration of the 15 
resulting alcohol. The product is further worked-up by simple gravimetric phase separation and 16 
then crystallized with 2 M HCl in diethyl ether to afford pure Melitracen HCl. All steps in the 17 
laboratory setup were concatenated and the setup was proven capable of producing a significant 18 
portion of the commercial quantities of Melitracen HCl. The flow setup profits from a reduced 19 
footprint, lower energy consumption, fewer synthetic steps and reduced raw material usage 20 
compared to the batch process. 21 
Keywords: Grignard alkylation, Flow chemistry, API synthesis, liquid phase separation. 22 
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Introduction 24 
The efficiency of the pharmaceutical industry has been a widely discussed topic throughout the 25 
past decade. The debate has been broad, ranging from early target drug development to the actual 26 
production and distribution of pharmaceuticals.1–6 Expiring patents and empty pipelines have 27 
forced pharmaceutical companies to look for alternative methods to remain competitive against 28 
generic manufacturers.7–9 Furthermore, the industry has one of the highest solvent-to-carbon 29 
ratios,10 which in combination with the fact that most of these solvents have high environmental 30 
impacts has given the industry a somewhat damaged reputation.5,10–13 In addition, the authorities 31 
have steadily increased the tightening of legislative requirements for pharmaceutical 32 
manufacturing, in both development and production.3,5 33 
With respect to the production of active pharmaceutical ingredients (APIs), the focus has 34 
especially been on batch methods and their insufficiency, especially their mass and heat transfer 35 
properties.14,15 As early as the 1970s, Popov16 suggested continuous manufacturing as a method 36 
for improving the efficiency of pharmaceutical production. However, it was not until the last 37 
decade that progress was seen. The establishment of the pharmaceutical round table and the 38 
increased interest from academia and industry have been driving the transformation 39 
forwards.4,5,17–20 The authorities have since 2002 acknowledged new production methods and 40 
strategies within manufacturing. Process analytical technology (PAT) approaches and 41 
Quality-by-Design (QbD) concepts have been important factors in the acceptance of continuous 42 
manufacturing by the authorities.9,21,22 43 
Earlier publications concerning the new paradigm of pharmaceutical manufacturing often 44 
focused on single synthesis steps and unit operations, often with the use of microreactor 45 
technology.23,24 Later trends have changed the focus towards multiple synthesis steps, 46 
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pharmacy-on-demand and end-to-end manufacturing.17–19,25 As the trend has moved from single 47 
step to end-to-end manufacturing,18 the previous out-scaling concept23 of microreactors has also 48 
been replaced by mini-scale flow systems.18,20,26–28 The scale-up of a continuous setup needed to 49 
meet full-scale requirements is often minor; hence the benefits such as mass and heat transfer are 50 
almost comparable to microreactor technology.15 51 
Reactions having multiple phases still pose a significant challenge within flow chemistry.29–31 52 
Flow reactors are known for being poor at handling solid material due to clogging issues, with 53 
some exceptions such as packed bed reactors with fixed catalytic material. Breakthroughs for 54 
flow reactors that can handle solid reactants or products have within recent years been 55 
demonstrated, such as the desulfurization of substituted thioimidazoles by Baxendal et al.32, the 56 
powder dosing unit for a CSTR demonstrated by Hu et al.33 and precipitation in flow 57 
demonstrated by Baxendal et al.34 58 
The pharmaceutical industry is notorious for their usage of solid compounds, either as 59 
reactants, intermediates or APIs.29,31 Low solubility is often a huge obstacle for applying the 60 
chemistry to a flow setup, unless alternative methods are applied.2,31 Solubility is one of the key 61 
parameters when designing a reactor setup and an instructive discussion may be found in 62 
Pedersen et al.20 In cases of high solubility, the simple use of a plug flow reactor (PFR) can be 63 
applied, often with great success and larger throughput.28,35 The challenging part then becomes 64 
the purification of the product from impurities and unreacted reactants, as well as the final 65 
isolation of the product. Many old batch processes utilize the benefits of precipitation as a 66 
purification step, hence altering an old batch process to fit a flow setup requires new ways to 67 
overcome these challenges.2,20,29 68 
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Grignard reactions serve as a commonly used method for the formation of carbon-carbon 69 
bonds in the development of APIs36,37. The exothermic behavior of the Grignard reaction makes 70 
it ideal for continuous production. Several demonstrations of Grignard reactions in flow have 71 
been done within the last decade: Kopach et al.38,39 demonstrated the use of a CSTR technology; 72 
Pedersen et. al20,26,40 demonstrated the use of a heterogeneous slurry filter reactor; Mateos et al.41 73 
studied the formation of ketone by nucleophilic Grignard addition to nitril groups by use of flow 74 
methods; Lonza42–44 has demonstrated the use of micro reactor technology. 75 
Chemistry 76 
As illustrated in Scheme 1, four synthetic steps are involved in the manufacturing of 77 
Melitracen HCl (6). The four steps are a classic Grignard addition to a ketone, a hydrolysis of a 78 
magnesium alkoxide, a dehydration of an alcohol and a salt precipitation to isolate the API. The 79 
Grignard addition is between 10,10-dimethylanthrone (10,10-DMA (1)) and 80 
3-(N,N-dimethylamino)propylmagnesium chloride (DMPC-MgCl (2)), resulting in formation of 81 
the magnesium alkoxide 3. The magnesium alkoxide 3 is then hydrolyzed to the alcohol 4 and 82 
dehydrated to form product 5. The last step is a crystallization of the API as a salt, where HCl is 83 
added to obtain the Melitracen HCl (6). 84 
Scheme 1: Syntheses of magnesium alkoxide 3, alcohol 4 and dehydrated product 5 in the 85 
manufacturing process of Melitracen HCl 6, from ketone 1 and Grignard reagent 2. 86 
 7 
O
+ ClMg N
ClMgO
N
N
HClHO
N
N
1 2 3
4 5 6
H2O/H3O
+
H+ HCl
 87 
Current Batch Synthesis 88 
The current batch synthesis involves individual synthetic steps, as illustrated in Figure 1. 89 
DMPC-MgCl 2 is made in-house before it is used, due to its limited storage shelf life, in a 90 
toluene-THF solvent mixture. THF is present in trace amounts in order to stabilize the 91 
magnesium in the Grignard reagents.45 A solution of 10,10-DMA 1 is prepared in toluene and is 92 
slowly transferred to the DMPC-MgCl 2, maintaining a temperature of 50°C. DMPC-MgCl 2 is 93 
used in an equivalence of 1.6 compared to 10,10-DMA 1. The formed magnesium alkoxide 3 is 94 
hydrolyzed with water and acetic acid (80%). The aqueous phase is discarded and concentrated 95 
hydrochloric acid (37%) is used to dehydrate alcohol 4 to form dehydrated product 5. Toluene is 96 
replaced with ethanol by a solvent swap. Crystallization of the dehydrated product 5 from the 97 
ethanol phase is done with HCl gas to obtain the final Melitracen HCl (6), which is subsequently 98 
isolated by filtration. 99 
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Figure 1: The operational steps involved in the current batch method and the simplification 101 
achieved by the flow setup. 102 
Investigational Strategy 103 
The API manufacturing strategy at H. Lundbeck A/S is focused on continuous production. 104 
Melitracen HCl synthesis currently occupies significant production facilities and is produced by 105 
routine batch synthesis procedures. The process shows potential for being redesigned to fit a 106 
continuous reactor setup, with potential for significant simplification of the operation and the 107 
synthetic route. This article describes the laboratory work for redesigning the process to fit a 108 
continuous reactor setup for the Grignard addition to the final Melitracen HCl crystallization. 109 
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Experimental Section 110 
Screening Experiments 111 
The routine batch synthesis for production of Melitracen HCl 6 was considered suitable for 112 
redesign into a flow process, as most of the synthetic steps are categorized as fast reactions.31 113 
The current batch methods could possibly be transferred directly into a flow setup, providing the 114 
common benefits achieved when changing from batch to continuous processing. However, 115 
additional savings could potentially be achieved with the flow setup if simplifications of aspects 116 
such as the solvent choice and synthetic steps were possible. Classic batch screening experiments 117 
were conducted to assist in the decision on and design of a flow setup and, based on these 118 
experiments, the flow setup decided on was to be experimentally verified afterwards. 119 
Solubility of Reactants and Products in Solvents 120 
The first consideration in the process for redesigning Melitracen HCl 6 synthesis is the 121 
solubility of reactants, intermediates and products. Solubility is one of the key parameters when 122 
designing a reactor setup. The primary focus was on the Grignard addition step, where reactants 123 
10,10-DMA 1, DMPC-MgCl 2 and magnesium alkoxide product 3 are of interest. DMPC-MgCl 124 
2 already has a high solubility and was not tested further. 10,10-DMA 1 is a solid starting 125 
material and needs to be dissolved before it can react with DMPC-MgCl 2. The solubility of 126 
10,10-DMA 1 should therefore be tested in potential solvents and at different temperatures. 127 
Magnesium alkoxide 3 is not easily isolated, as the magnesium halide part easily reacts with 128 
water and moisture. Instead of determining the exact solubility of magnesium alkoxide 3, a 129 
qualitative first estimate of its capability to stay in solution could be sufficient. The requirement 130 
is, of course, that the concentration of magnesium alkoxide 3 in the reaction mixture is 131 
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representative of the concentrations of the 10,10-DMA 1 and DMPC-MgCl 2 intended for the 132 
synthesis. The later synthetic steps should be tested accordingly for solubility where necessary, 133 
since low solubility in these steps could require a lower concentration of 10,10-DMA 1 and 134 
DMP-MgCl 2 to have a fully operational flow setup from start to end of the synthesis. 135 
The solubility experiments on 10,10-DMA 1 focused on three solvents to be verified: toluene, 136 
tetrahydrofuran (THF) and 2-methyltetrahydrofuran (MeTHF), all of which are suitable 137 
candidates for later full-scale production. The solubility temperature was tested up to 20°C, 138 
which is to be considered the high limit due to ambient temperatures if no heat tracing should be 139 
applied to pumps and pipes. Figure 2 shows the solubility of 10,10-DMA 1 in the three solvents, 140 
where THF shows a significantly higher solubility than toluene or MeTHF. 141 
 142 
Figure 2: The solubility of 10,10-DMA 1 in toluene (), THF () and MeTHF (). The 143 
10,10-DMA 1 has high solubility even at low temperatures in the tested solvents. The solubility 144 
in THF is significantly higher compared to MeTHF and Toluene (approximately 100 g/L more 145 
10,10-DMA 1). 146 
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The significantly higher solubility of 10,10-DMA 1 in THF makes it obvious to use THF. If 147 
toluene were to be used as in the batch process, trace amounts of ether would still be needed to 148 
stabilize the magnesium in DMPC-MgCl 2. 149 
The concentration of 10,10-DMA 1 in THF was set to the lower side of 20°C (1.8 mol/L, 400 150 
g/L) to minimize the risk of precipitation while operating a flow setup. The DMPC-MgCl 2 was 151 
available at approximately 1.5 M concentration in THF from the production and it was decided 152 
to proceed with this concentration. A couple of quick qualitative batch experiments were carried 153 
out to verify whether the magnesium alkoxide 3 could remain soluble in the reaction mixture, as 154 
it was not possible to isolate the unstable magnesium alkoxide 3 for a solubility study. These 155 
experiments came out positive for the desired concentrations of 10,10-DMA 1 and DMPC-MgCl 156 
2 and no further testing of the solubility of magnesium alkoxide 3 was found necessary. 157 
Phase Separation: Organic Phase and Aqueous Waste 158 
 159 
A batch experiment, representing the expected concentration for the flow setup, was used to 160 
verify the potential for phase separation of THF from the aqueous phase. The DMPC-MgCl 2 161 
was slowly added in excess amounts with a dripping funnel to a round-bottom flask of the 162 
10,10-DMA 1 solution. The mixture was afterwards hydrolyzed with water and acetic acid 163 
(80%). The addition of the acid caused the pH of the mixture to become slightly acidic (pH ∼6) 164 
and an one-phase mixture was achieved. The pH was adjusted with aqueous ammonia (25%) and 165 
at pH 8 a two-phase mixture appeared. Alcohol 4 was distributed with 63% in the organic phase 166 
and 37% in the aqueous, according to HPLC assay. Adjusting the pH in the aqueous phase to 10 167 
with additional aqueous ammonia (25%) resulted in an additional organic phase, with less than 168 
1% alcohol 4 left in the aqueous phase. 169 
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Alcohol 4 in the organic phase was then dehydrated with hydrochloric acid (37%), followed by 170 
adjustment of the pH to 10 with aqueous ammonia (25%). Adjusting the pH to 10 allowed a 171 
phase separation with more than 99% of the product in the organic phase and with a ∼99% purity 172 
of the dehydrated product 5. During the hydrolysis and dehydration, a minor precipitation of 173 
solid material was formed that easily dissolved as the reaction progressed and should therefore 174 
not be a major concern for a flow setup. 175 
At pH ≥ 10 the tertiary amine is completely deprotonated, causing the products 4 and 5 to 176 
become almost insoluble in water, thereby achieving excellent separation. At pH ≤ 10 the tertiary 177 
amine becomes protonated and is soluble both in the aqueous and organic phase. If a clean phase 178 
separation had not been possible, changing the synthesis solvent to MeTHF could have 179 
simplified the workup of the products 4 or 5 from the aqueous phase, as MeTHF is not miscible 180 
with water. 181 
One-Step Hydrolysis and Dehydration 182 
The ability to phase separate both the alcohol 4 and the dehydrated product 5 in THF enabled a 183 
simplification of the targeted flow method. Ideally, hydrolysis and dehydration should be 184 
possible in one step, hence saving a phase separation and combining two synthetic steps into one. 185 
Screening for a potential acid for the one-step hydrolysis and dehydration was done, focusing on 186 
acetic acid and hydrochloric acid, either separately or in combination. Table 1 shows the results 187 
of the product formation based on the different acid systems. 188 
Table 1: Screening of different acids for direct hydrolysis and dehydration of the magnesium 189 
alkoxide 3 to the dehydrated product 5. 190 
Acid Solution Product (%) Phase Separation (%) 
HCl 37% (aq.) Dehydrated 5 (100%) >99 
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AcOH 80% (aq.) Alcohol 4 (100%) >99 
HCl 37% (aq.)/AcOH 80% (aq.) (1:1) Dehydrated 5 (90%) 
Alcohol 4 (10%) 
>99 
 191 
As seen in Table 1, only hydrochloric acid was able to hydrolyze and dehydrate the 192 
magnesium alkoxide mixture in one step. The experiment with hydrochloric acid resulted in 193 
significant heat development and an immediate precipitation of solids that potentially could be 194 
critical, even though it dissolved within a few minutes. An additional set of screening 195 
experiments was done to verify the potential of a lower concentration of hydrochloric acid. 196 
These experiments were carried out to verify whether the immediate precipitation of solid could 197 
be avoided and whether the energy released from the hydrolysis and dehydration could be 198 
distributed, as both steps are exothermic. Equal volumes of hydrochloric acid with different 199 
concentrations (1, 3, 6, 9 and 12 M) were used. For the concentrations lower than 6 M, it was not 200 
possible to achieve full dehydration at ambient temperature. For the concentrations equal to 6 M 201 
and higher, full dehydration was obtained, but all concentrations resulted in precipitation of a 202 
white solid that dissolved after few minutes of standing. From a production and environmental 203 
perspective, the more concentrated hydrochloric acid is the optimal choice; less aqueous waste is 204 
generated if the acid used is stoichiometric. Given the fact that precipitation could not be avoided 205 
and the production perspective, it was decided to proceed with 12 M hydrochloric acid. 206 
Precipitation of Melitracen HCl from THF 207 
The dehydrated product 5 was crystallized as the final HCl salt in the THF in a batch 208 
experiment, in order to remove a solvent swap to ethanol. The crystallization was carried out 209 
with 2 M HCl in Et2O, as this was considered more suited for a later flow process and more 210 
easily implemented in the laboratory setup. An equivalence of 1.1 HCl was used and the 211 
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requirement was an achievement of pH<2. The mixture was kept stirred during the 212 
crystallization and carried out at ambient temperature. After 10 minutes, fine white solids started 213 
to form, followed by a massive precipitation of Melitracen HCl 6. The Melitracen HCl 6 was 214 
filtered with a Büchner funnel and washed with THF. The isolated yield was 80% and within the 215 
specifications for the in-house analysis methods used in the routine production (CHN, TGA, 216 
UV-vis, HPLC, melting point). Figure 3 is a microscope picture of the isolated Melitracen HCl 6. 217 
For full-scale production, the HCl gas would still be more desirable for the crystallization and the 218 
2 M HCl in Et2O merely serves as a proof of concept for the laboratory flow setup. 219 
 220 
Figure 3: Microscope picture of the isolated Melitracen HCl 6 from the THF solution. 221 
Flow Process 222 
The initial batch screening experiments all indicated that the chemistry should be run in PFRs. 223 
This decision is based on several parameters from the screening experiments. In particular, the 224 
high solubility of the reactants and products makes the synthesis ideal for PFRs. Additionally, all 225 
of the synthesis steps are categorized as fast (full conversion within minutes) and hence small 226 
reactor volumes can be used. The final setup is illustrated in Figure 4 as a flow sheet. All tubing 227 
was 1/8” OD and 1/16” ID and made from PTFE; the T-mixer was of PEEK material ID 0.04”. 228 
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All synthetic steps were performed at ambient temperature, with no active cooling or heating. If 229 
the reactor system was to be scaled significantly, consideration of active cooling and heating 230 
should be taken into account due to potential safety and control related issues. Every step, except 231 
for the addition of acetic acid and the decanter phase separation, is exothermic. The decanter was 232 
a 100 mL glass bottle, fitted for the purpose with an in-house-made PTFE lid. After the Grignard 233 
addition (T1,C1) of DMPC-MgCl 2 to 10,10-DMA 1, a flow IR 10 µL head from Mettler Toledo 234 
was applied for in-line monitoring of the conversion and reaction. After the acetic acid addition 235 
(T3,C3), a 100 psi back pressure regulator (BPR) was applied to avoid boiling of the THF due to 236 
the hydrolysis and dehydration taking place at the HCl addition (T2,C2). The choice of placing 237 
the BPR is due to precipitation of solid material right after the HCl addition that is fully 238 
dissolved throughout the acetic acid coil. The HCl precipitation was done by collection of the 239 
two streams in a flask. A number of different pumps were used, all of them being positive 240 
displacement pumps for dosing purposes. Knauer Azura P 2.1S HPLC pumps with 10 mL 241 
stainless steel pump heads (P1 and P2) were used for the 10,10-DMA (1) and DMPC-MgCl (2); 242 
a Syrris Asia pump (dual pump) equipped with 0.5 and 1.0 mL glass syringes was used for both 243 
hydrochloric acid (P3) and acetic acid (P4). A Merck-Hitachi HPLC pump with a 10 mL 244 
stainless steel pumphead was used for the aqueous ammonia (P5) and Ismatec Reglo RH00 245 
piston pumps were used for the decanter outlet (P6) and the 2 M HCl in Et2O (P7). The two 246 
Knauer pumps were specially ordered with PTFE gasket intended for Grignard reagents and THF 247 
solvent. The remaining pumps were chosen based on availability in the laboratory. The flow rate 248 
was determined in accordance with the maximum capacity of each pump and the limitation was 249 
the pump used for the acetic acid. 250 
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 252 
Figure 4: Flow sheet of the flow reactor setup for the redesign of the Melitracen HCl synthesis. 253 
Pump (P), Coil (C), T-mixer (T), Infrared In-line flow cell (IR), Back pressure regulator (BPR). 254 
Results and Discussion 255 
Stepwise Verification of Flow Reactor Parts 256 
A stepwise implementation and verification of each step was done to minimize the risk of 257 
operational problems, while operating the entire setup as illustrated in Figure 4. The major risks 258 
were considered to be clogging issues and separation performance. 259 
The Grignard addition of DMPC-MgCl 2 to 10,10-DMA 1 was the first part to be verified and 260 
an equivalence of 1.1 DMPC-MgCl 2 was used to ensure full conversion of 10,10-DMA 1. Only 261 
a few minutes of residence time were needed for the reaction to achieve full conversion of the 262 
10,10-DMA 1. The reaction was easily followed visually, as the magnesium alkoxide 3 becomes 263 
dark red/orange. The product stream was collected in a flask, where it turned to a more orange-264 
like appearance over time. 265 
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Implementation of the HCl stream for hydrolysis and dehydration caused boiling of the THF 266 
solvent, but full conversion was achieved within minutes. Implementing the acetic acid stream 267 
resulted in some alteration of the setup to account for the boiling of the THF, as full conversion 268 
was not achieved. A back pressure regulator (BPR) of 100 psi was added to prevent the boiling 269 
of the THF (65 °C at STP). The BPR provided a stable flow that ensured a steady residence time 270 
in the HCl coil (C2), resulting in the desired full conversion of the magnesium alkoxide 3 to the 271 
dehydrated product 5. Adding the aqueous ammonia stream to the setup caused precipitation of 272 
ammonium chloride salt. The precipitate was easily dissolved by addition of water. Due to lack 273 
of pumps, it was decided to dilute the acetic acid to 40% from the original 80% and to double the 274 
flow rate. From a production perspective, an additional pump with water would be better suited 275 
as 80% acetic acid is the standard concentration in production. Acetic acid serves to assure that 276 
the magnesium salt complex remains soluble after pH adjustment to basic conditions. The BPR 277 
was originally implemented right after the HCl coil, but the white solid precipitate later caused 278 
clogging of the BPR, so it was moved to be after the acetic acid stream where a full liquid 279 
homogeneous phase was present. The choice of not moving it to be after the aqueous ammonia 280 
coil was due to a small risk of having precipitation upon the addition thereof, as this was 281 
observed in a previous run. At the end of the acetic acid addition during all adjustments, a full 282 
one-phase homogeneous stream was constantly present and it was considered more stable to add 283 
the BPR at this point in case of any fluctuation. 284 
Having the entire setup running, the decanter was tested for the setup. A previous flow setup 285 
had proved the decanter’s capability for separating organic and aqueous phases from each other, 286 
so that a single experiment was enough to demonstrate the decanter for this separation. The last 287 
stream to be implemented was the 2 M HCl (Et2O) stream for crystallization. At first, mixing of 288 
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the two streams was attempted in a T-mixer (2.5 mm ID), but the low pressure pumps used 289 
(Ismatec pumps) could not deliver a high enough pressure to avoid clogging. The clogging was 290 
caused by evaporation of the solvents due to the low boiling points of both THF and Et2O and 291 
the crystallization of Melitracen HCl (6) happening in the T-mixer. As an alternative, the two 292 
streams (P6 and P7) were pumped individually into the collecting bottle. No optimization was 293 
done to control the crystallization, as this was not the scope of the project, and for a full-scale 294 
setup HCl gas would be a preferred choice. Figure 5 shows the fractions collected from the setup. 295 
 296 
Figure 5: The collected fractions of product streams from the setup during continuous operation. 297 
To the left is the aqueous waste from the decanter, at the center is the organic phase containing 298 
dehydrated product 5 and to the right is the crystalline Melitracen HCl 6 API and the mother 299 
liquid. 300 
Operation of Full Flow Setup 301 
The final flow setup, as illustrated in Figure 4, was operated for 300 minutes under steady state 302 
conditions. The experiment was terminated at the point of complete utilization of the 2 M HCl 303 
(Et2O). For the first 30 minutes the setup was not in steady state due to a tube burst and fittings 304 
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around the IR flow cell, but a steady state was achieved shortly after replacement of the broken 305 
fittings. The tube burst was a result of a clog formed from Grignard reagent reacting with 306 
residual water in the IR flow cell from previous cleaning. The flow rate of the system is given in 307 
Table 2 and Table 3 provides the residence times in the important parts of the reactor. 308 
Table 2: The reactor configurations and residence times, along with important observations, for 309 
the Melitracen HCl 6 synthesis as operated with the flow setup (Figure 4). 310 
Reactor part Flow Rate 
(mL/min) 
Reactor 
Volume (mL) 
Residence 
Time (s) 
Observation 
Coil 1 4.5 4.95 66 Deep red color from reaction. 
Temperature higher than ambient, 
lower than the boiling point of THF. 
Coil 2 5.5 1.98 21.6 Temperature is above the boiling 
point of THF, 100 psi suppress 
boiling. 
Stream becomes transparent with a 
white solid that disappears into an 
one-phase system. 
pH < 2 
Coil 3 8.0 0.99 7.4 One-phase system 
pH < 2 
Coil 4 9.9 1.98 6.0 Two-phase system 
pH > 10 
Decanter 
(Org/Aq) 
9.9 (4.5/5.4) 100 606.1 Two-phase system 
pH > 10 
 311 
Table 3: The flow rates and concentrations of the different reactants used in the flow setup. 312 
Reactants Flow rate (mL/min) Concentration (M) Equivalence to 10,10-DMA 1 
10,10-DMA 1 2.0 1.8 1.0 
DMPC-MgCl 2 2.5 1.5 1.05 
HCl (aq) 1.0 12 (37%) 3.33 
AcOH (aq) 2.50 7 (40%) 4.86 
NH3 (aq) 1.9 13.4 (25%) 7.07 
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HCl (Et2O) 2.25 2 1.25 
 313 
An IR flow cell was placed after coil 1 and was used to follow and ensure that full conversion 314 
of 10,10-DMA 1 was achieved. Figure 6 shows the carbonyl peak of the 10,10-DMA 1 as it 315 
progressed throughout the experiment. The trend line absorbance intensity of the peak is based 316 
on area to zero baseline for the IR region of 1610-1580 cm-1 and is given in arbitrary units. The 317 
off-line HPLC data in Table 4 confirms full conversion of 10,10-DMA 1. The replacement of the 318 
tubing caused an exposure of the magnesium alkoxide 3 to the surrounding atmosphere (i.e. 319 
moisture in the air), resulting in the deposit of magnesium salts on the IR diamond window. 320 
Despite an attempt to clean the window, some deposit was still present, causing the small offset 321 
from the zero baseline, which explains why zero is not achieved. 322 
 323 
Figure 6: The IR data on the flow setup run, following the peak of the carbonyl functional group 324 
of 10,10-DMA (1) and the reference samples for off-line HPLC analysis given in Table 4. Steady 325 
Sample
No. 1
Sample
No. 2
Sample
No. 3
Sample
No. 4
Sample
No. 5
Sample
No. 6
Sample
No. 7
Sample
No. 8
Stable Flow
HCl (aq) Pump 
stopped briefly
Out of HCl 2M
in Et2O
0 50 100 150 200 250 300 350
0
5
10
15
20
0
5
10
15
20
0 50 100 150 200 250 300 350
Pe
ak
 a
re
a 
(a
.u
.)
Time (min)
10,10-DMA
Carbonyl Peak
 21 
state conditions were achieved after 30 minutes; the initial 30 minutes of unstable flow were 326 
related to bursting and replacing of tubing and fittings. 327 
A portion of the Melitracen HCl (6) was collected by filtration in a Büchner funnel, washed 328 
with THF and dried in a vacuum oven at 50 °C for 24 hours. The product was subjected to 329 
complete release analysis for the API and all product attributes were found to be within 330 
specification. A total of 300 g of dry Melitracen HCl (6) was isolated from the flow setup, 331 
requiring a consumption of approximately 240 g 10,10-DMA (1) starting material. 332 
Table 4: The HPLC samples, where samples were collected from the aqueous waste stream of 333 
the decanter, the crystallized Melitracen HCl (6) and the mother liquid, and a few from the 334 
organic phase of the decanter. 335 
Sample 
No. 
Compound Crystallized 
Product 
(Area%) 
Mother 
Liquid 
(Area%) 
Decanter 
Aqueous 
(Area%) 
Decanter 
Organic 
(Area%) 
1 Melitracen (5 or 6) 
Alcohol (4) 
10,10-DMA (1) 
Other Impurities 
100 
nd 
nd 
nd 
97.65 
nd 
2.1 
0.2 
62.0 
38.0 
nd 
nd 
No sample 
2 Melitracen (5 or 6) 
Alcohol (4) 
10,10-DMA (1) 
Other Impurities 
100 
nd 
nd 
nd 
97.8 
nd 
2.0 
0.2 
37.8 
62.1 
nd 
nd 
No sample 
3 Melitracen (5 or 6) 
Alcohol (4) 
10,10-DMA (1) 
Other Impurities 
100 
nd 
nd 
nd 
96.3 
nd 
3.5 
0.2 
20.5 
79.5 
nd 
nd 
No sample 
4 Melitracen (5 or 6) 
Alcohol (4) 
10,10-DMA (1) 
Other Impurities 
100 
nd 
nd 
nd 
99.0 
nd 
0.8 
0.2 
nd 
100 
nd 
nd 
No sample 
5 Melitracen (5 or 6) 
Alcohol (4) 
99.9 
0.1 
99.1 
nd 
nd 
100 
No sample 
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10,10-DMA (1) 
Other Impurities 
nd 
nd 
0.7 
0.2 
nd 
nd 
6 Melitracen (5 or 6) 
Alcohol (4) 
10,10-DMA (1) 
Other Impurities 
100 
nd 
nd 
nd 
99.3 
nd 
0.5 
0.2 
nd 
100 
nd 
nd 
100 
nd 
nd 
nd 
7 Melitracen (5 or 6) 
Alcohol (4) 
10,10-DMA (1) 
Other Impurities 
100 
nd 
nd 
nd 
39.8 
60.2 
nd 
nd 
39.3 
60.7 
nd 
nd 
99.8 
0.2 
nd 
nd 
8 Melitracen (5 or 6) 
Alcohol (4) 
10,10-DMA (1) 
Other Impurities 
100 
nd 
nd 
nd 
56.4 
43.6 
nd 
nd 
26.2 
73.8 
nd 
nd 
100 
nd 
nd 
nd 
 336 
Conclusions 337 
A full redesign of a current batch synthesis to a full flow setup has been possible, from the 338 
starting material to the final salt crystallization of the active pharmaceutical ingredient, 339 
Melitracen HCl. The flow process was significantly simplified compared to the batch process, 340 
with removal of a phase separation and usage of tetrahydrofuran (THF) only as a solvent 341 
compared to the previous toluene-THF solvent mixture. All synthetic steps were carried out at 342 
ambient temperature, whereas routine batch production requires active heating (up to 50°C) and 343 
cooling in several steps. The crystallization of the Melitracen HCl was proven possible in THF 344 
with 2 M HCl in diethyl ether (Et2O) and eliminated a solvent swap to ethanol. The 345 
crystallization was not optimized and would most likely be done with HCl gas, with an expected 346 
additional gain in yield from the lower volume of solvent. The isolated yield in the given study 347 
was approximately 85%. The phase separation achieved with the decanter was higher than 99% 348 
product in the organic phase, with a HPLC purity of greater than 99%. The isolated Melitracen 349 
HCl was analyzed in accordance with the in-house release methods required for current batch 350 
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production and all measurements were in accordance with requirements. A production of 60 g/h 351 
of isolated Melitracen HCl can be achieved with the flow setup. Furthermore, the setup 352 
demonstrated great robustness towards fluctuations in reactant streams. The one-step hydrolysis 353 
and dehydration could potentially be applicable for other Grignard additions, as could the 354 
subsequent decanter phase separation. 355 
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